株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医療関連感染 (HAI) 管理市場

Hospital Acquired Infection (HAI) Control Markets

発行 Kalorama Information 商品コード 304515
出版日 ページ情報 英文 242 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
医療関連感染 (HAI) 管理市場 Hospital Acquired Infection (HAI) Control Markets
出版日: 2017年02月22日 ページ情報: 英文 242 Pages
概要

当レポートでは、世界および米国における医療関連感染 (HAI) - 院内感染やその他の治療・医療行為関連の感染症 - の管理市場について調査し、主な感染症の予防方法や検査手法、治療手段の概要と動向、地域別市場分析、今後の市場参入機会、主要企業企業のプロファイルといった情報を取りまとめてお届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクションと業界動向

  • 概要
  • 一般的な院内感染
  • 感染の説明
  • 世界の人口統計
  • 運営委員会
  • 感染症の疫学・ラボ容量
  • 医療保険制度改革法 (ACA) 資金
  • 新たな感染症プログラム
  • 米保健福祉省:予算ハイライト
  • 全米医療安全ネットワーク (NHSN)
  • 医療感染調査プロセス
  • 医薬品メーカー・マーケッター動向

第3章 感染予防

  • 概要
  • 市場概要
  • リスクの高い施設・部署
  • 装置・ソリューション
  • 熱/蒸気消毒
  • 化学・ガス消毒
  • 紫外線消毒
  • 競合分析

第4章 感染検査

  • 概要
  • 総市場規模・予測
  • 院内感染検査
  • DNAシーケンシング
  • 主要な重症院内感染検査
  • 発展
  • 競合分析

第5章 感染症治療

  • 概要
  • 総市場規模・予測
  • 抗菌治療の原理
  • 抗菌製品の分類
  • 市場規模・売上構成:抗生剤クラス別
  • 感染症・薬剤耐性
  • 公認感染症プログラムの指定
  • 新たな発展
  • 競合分析

第6章 医療関連感染管理の市場機会

  • 市場の検討事項
  • 市場概要

第7章 企業プロファイル

  • イントロダクション
  • ABBOTT LABORATORIES
  • ADVANCED STERILIZATION PRODUCTS
  • ALERE
  • ASTRAZENECA
  • BAYER
  • BECTON, DICKINSON AND COMPANY
  • BELIMED
  • BIOMERIEUX S.A.
  • CANTEL MEDICAL CORP.
  • DANAHER CORPORATION
  • ECOLAB, INC.
  • GETINGE GROUP
  • GLAXOSMITHKLINE PLC
  • MERCK & CO.
  • MERCK & CO.
  • PFIZER, INC.
  • ROCHE
  • サクラ精機
  • STERIS PLC
  • TSO3, INC.

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI15261546

Hospital Acquired Infection (HAI) Control Markets focuses on the market for preventing, testing, and treating infections in the healthcare environment. Major consideration is given to bacterial nosocomial infections because they are the most frequent type of infections spread in the healthcare delivery setting and the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations. The report provides a market analysis for each of three areas: prevention (sterilization and disinfection equipment), testing, and treatment, detailing the following market data:

  • The Global Market for Hospital Infection Control, 2010-2021
  • The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
  • The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)
  • The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers' Shares, Estimates for 2016
  • The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
  • The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers' Shares Estimates for 2016
  • The Global Market for Hospital Infection Treatment, 2010-2021
  • The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Treatment, Leading Suppliers' Shares, Estimated Share for HAIs for 2016
  • Annual Sales of Select Antibacterial Products, 2016
  • The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)
  • The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)
  • The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)
  • The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])
  • Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)

A nosocomial infection is a new infection that develops in a patient during hospitalization or during a stay at a health facility. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a hospital-acquired infection (or, more generically, healthcare associated infection). The report provides the following data regarding nosocomial infections:

  • Frequency of the Most Common Nosocomial Infections
  • Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)
  • Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections; Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)
  • Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, β-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)
  • Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)
  • Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)

Hospital acquired infections share many of the challenges faced by the larger healthcare industry. Both challenges and industry trends are discussed in Hospital Acquired Infection (HAI) Control Markets, as well as market growth drivers and market growth inhibitors. One of the challenges facing the market is that increased attention to identification in the emergency department (ED) is needed to reduce risk and control exposure. With rapid identification, placing patients in isolation, whether they are colonized or infected, will likely make a difference in the resistance rates and spread of microorganisms in hospitalized patients.

The majority of competitive participation for healthcare infection control is in the United States and Europe. However, competition is steadily escalating in these areas, which is encouraging more participation in other regions such as Asia and Latin America. The report profiles important players in the current competitive landscape, including:

  • 3M
  • Abbott Laboratories
  • AbbVie
  • Advanced Sterilization Products
  • Alere
  • AstraZeneca
  • Bayer
  • Becton, Dickinson
  • Belimed
  • bioMérieux
  • Cantel Medical
  • Danaher
  • Ecolab
  • Getinge AB
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer, Inc.
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sakura Seiki, Co., Ltd.
  • Steris plc
  • TSO3

Market analysis in this report considers primarily the epidemiological considerations and the size of patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

OVERVIEW

THE NOSOCOMIAL INFECTION

  • Table 1-1: Frequency of the Most Common Nosocomial Infections

MARKET SCOPE

RESEARCH METHODOLOGY

INDUSTRY CHALLENGES

  • Table 1-2: Growth Drivers and Inhibitors

TOTAL SIZE AND GROWTH OF THE MARKET

  • Table 1-3: The Global Market for Hospital Infection Control, 2010-2021
  • Figure 1-1: Global Market for Hospital Infection Control, 2010-2021

ISSUES AND TRENDS AFFECTING MARKET

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

OVERVIEW

  • Introduction to Pathogens
  • Classification of Antibacterial Organisms

COMMON HOSPITAL (NOSOCOMIAL) INFECTIONS

DESCRIPTION OF INFECTIONS

  • Acinetobacter Baumannii
  • Clostridium Difficile
  • Gastroenteritis
  • Hospital-Acquired Pneumonia (HAP)
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
  • Stenotrophomonas Maltophilia
  • Tuberculosis
  • Urinary Tract Infections
  • Vancomycin-Resistant Enterococcus
  • Ventilator-Associated Pneumonia (VAP)
  • Patient Risk Factors
  • General Populations at Risk for Infection
  • Hospital Acquired Infection (HAI) Control Markets
  • February ii 2017 © Kalorama Information
  • Table 2-1: Global Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region (Cancer [newly diagnosed; active treatment], Diabetes, HIV/AIDS, Surgical Procedure, ESRD/Dialysis, Organ Transplants, Cystic Fibrosis; United States, Europe, Other Regions, World)

WORLD DEMOGRAPHICS

  • Figure 2-1: The Global Population, 2005-2050
  • Table 2-2: Global Population Trends Age 65+, 2000-2050
  • Assessing the Problem: Nosocomial Infection Statistics
  • Figure 2-2: U.S. Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (MRSA, C. diff, Others)
  • Figure 2-3: European Union Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (SSI, Bloodstream, MRSA, Lower RTI, UTI, Others)
  • Hospital Length of Stay
  • U.S. GOVERNMENT'S NATIONAL PLAN TO PREVENT HEALTHCARE ASSOCIATED INFECTIONS (HAIS)

STEERING COMMITTEE

EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES

AFFORDABLE CARE ACT (ACA) FUNDING

EMERGING INFECTIONS PROGRAM

  • Table 2-3: U.S. States ACA HAI Prevention Infrastructure Funding Awards, 2013-2016

THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: 2017 BUDGET HIGHLIGHTS

  • Table 2-4: U.S. Department of Health & Human Services Fiscal Budget, 2015-2017

NATIONAL HEALTHCARE SAFETY NETWORK

  • Table 2-5: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR), 2010-2014
  • Figure 2-4: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR) 2012 through 2014

HEALTHCARE INFECTION SURVEILLANCE PROCESS

PHARMACEUTICAL MANUFACTURER AND MARKETER TRENDS

  • Trends in Partnerships and Alliances
  • Developers Trends

CHAPTER THREE: INFECTION PREVENTION

OVERVIEW

  • Table 3-1: Methods of Sterilization and Disinfection

MARKET OVERVIEW

  • Table 3-2: The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
  • Healthcare Infection Prevention Market by Geographical Region
  • Table 3-3: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total) .. 56
  • Methods of Transmission

HIGH-RISK FACILITIES OR DEPARTMENTS

  • Acute Care Hospitals
  • Long-term Care Facilities
  • Outpatient Settings
  • Technology Overview
  • Table 3-4: Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
  • Sterilization vs. Disinfection

EQUIPMENT AND SOLUTIONS

  • Table 3-5: Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)

HEAT/STEAM STERILIZATION

  • Product Examples

CHEMICAL AND GAS STERILIZATION

  • Disinfecting Agents and Medical Device Components
  • Sterilants
  • Table 3-6: Summary of Advantages and Disadvantages of Chemical Agents Used as Chemical Sterilants or as High-Level Disinfectants
  • Table 3-7: Comparison of the Characteristics of Selected Chemicals Used as High-Level Disinfectants or Chemical Sterilants
  • Product Examples
  • Mid-Level Disinfectants
  • Table 3-8: Comparison of the Characteristics of Selected Hospital Disinfectants for General Disinfection of Environmental Surfaces

RADIATION STERILIZATION

  • Product Examples
  • Table 3-9: Developments, Healthcare Infection Prevention

COMPETITIVE ANALYSIS

  • Table 3-10: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers' Shares, Estimates for 2016

CHAPTER FOUR: INFECTION TESTING

OVERVIEW

TOTAL MARKET SIZE AND FORECAST

  • Table 4-1: The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
  • Healthcare Infection Testing Market by Geographical Region
  • Table 4-2: The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)

TESTING FOR NOSOCOMIAL INFECTIONS

  • Drug-Resistance/Susceptibility Testing
  • Genotypic Methods

DNA Sequencing

  • Solid-phase Hybridization Techniques
  • Hospital Acquired Infection (HAI) Control Markets
  • February iv 2017 © Kalorama Information
  • Microarrays
  • Real-time Polymerase Chain Reaction Techniques
  • Phenotypic Methods
  • Phage-based Assays
  • Colorimetric Methods
  • The Nitrate Reductase Assay
  • Chromogenic Testing
  • Table 4-3: Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)

SPECIFIC SERIOUS HEALTHCARE INFECTION TESTING

  • Table 4-4: Tested Samples, Pathogens Isolated by Infection Type (Surgical Site Infection [SSI], Central Line-associated Bloodstream Infections [CLABSI], Catheter-associated Urinary Tract Infections [CAUTI])
  • Acinetobacter Baumannii
  • Carbapenem-resistant Enterobacteriaceae
  • Clostridium Difficile
  • Product Examples
  • Hospital-Acquired Pneumonia
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Ventilator-Associated Pneumonia
  • Table 4-5: Significant Approvals for Detecting Serious Healthcare Infections
  • Figure 4-1: HAI Test Approvals in the U.S. by Year and Type, 2000-2016 (Staph/MRSA, C. diff, Others)
  • Figure 4-2: Distribution of Diagnostic Test Approvals with HAI Indications by Pathogen, All Approvals, 2000-2016 (MRSA, C. diff, CRE, VRE, GBS, Others)
  • Table 4-6: Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections; Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)

DEVELOPMENTS

  • Table 4-7: Ongoing Developments, Healthcare Infection Testing
  • Table 4-8: Pathogen/Infection Detection Trials by Type

COMPETITIVE ANALYSIS

  • Table 4-9: The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers' Shares Estimates for 2016

CHAPTER FIVE: INFECTION TREATMENT

OVERVIEW

TOTAL MARKET SIZE AND FORECAST

  • Table 5-1: The Global Market for Hospital Infection Treatment, 2010-2021
  • Healthcare Infection Treatment Market by Geographical Region
  • Table 5-2: The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)

PRINCIPLES OF ANTI-BACTERIAL THERAPY

  • Infecting Organism
  • Antibiotic Sensitivity Testing
  • Site of Infection
  • Host Defenses and Organ Function
  • Antibiotic Pharmacokinetics
  • Monitoring Therapy

CLASSIFICATIONS OF ANTIBACTERIAL PRODUCTS

  • Aminoglycosides
  • Carbapenems
  • Cephalosporins
  • Glycopeptides
  • Macrolides
  • Penicillins
  • Quinolones
  • Sulfonamides
  • Tetracyclines

MARKET SIZE AND SALES DISTRIBUTION BY ANTIBIOTIC CLASS

  • Table 5-3: Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, β-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)
  • Table 5-4: Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)

INFECTIONS AND DRUG RESISTANCE

  • Easing Approvals of Antibiotics
  • Table 5-5: CDER NME NDAs/BLAs Filings and Approvals as of 12/9/15

QUALIFIED INFECTIOUS DISEASE PROGRAM DESIGNATIONS

  • Causes of Drug Resistance
  • Drug Resistance in Select Populations
  • Treatment Guidelines
  • Table 5-6: Antibiotics with Difficult Penetration
  • Table 5-7: Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)

NEW DEVELOPMENTS

  • Table 5-8: New Developments, Healthcare Infection Treatments, as of December 2016
  • Table 5-9: Infection Treatments in Development by Phase, as of December 2016
  • Table 5-10: Infection Treatment Drugs in Development by Route of Administration, as of December 2016
  • New Developments in Biotherapies for Infection Treatment

COMPETITIVE ANALYSIS

  • Hospital Acquired Infection (HAI) Control Markets
  • February vi 2017 © Kalorama Information
  • Table 5-11: The Global Market for Hospital Infection Treatment, Leading Suppliers' Shares, Estimated Share for HAIs for 2016
  • Table 5-12: Select Treatment Options for Serious Bacterial Infections (Type, Brand, and Manufacturer) .. 166
  • Leading Products
  • Table 5-13: Annual Sales of Select Antibacterial Products, 2016

CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION CONTROL

MARKET CONSIDERATIONS

MARKET OVERVIEW

  • Table 6-1: The Global Market for Hospital Infection Control, 2010-2021
  • Figure 6-1: The Global Market for Hospital Infection Control, 2010-2021
  • Figure 6-2: The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)
  • Healthcare-Acquired Infection Distribution by Setting
  • Figure 6-3: The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)
  • Figure 6-4: The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)
  • Healthcare Infection Control Market by Geographical Region
  • Table 6-2: The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • Figure 6-5: The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)
  • Figure 6-6: The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)
  • Developed and Emerging Market Analysis
  • Table 6-3: Developed vs. Emerging Markets
  • Figure 6-7: The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])

CHAPTER SEVEN: COMPANY PROFILES

INTRODUCTION

  • Figure 7-1: Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)
  • 3M
  • Table 7-1: 3M Company Corporate Summary
  • Company Overview
  • Company Performance

ABBOTT LABORATORIES

  • Table 7-2: Abbott Laboratories Corporate Summary
  • Company Overview
  • Company Performance
  • ABBVIE
  • Table 7-3: AbbVie Corporate Summary
  • Company Overview
  • Company Performance

ADVANCED STERILIZATION PRODUCTS

  • Table 7-4: Advanced Sterilization Products Corporate Summary
  • Company Overview
  • Company Performance

ALERE

  • Table 7-5: Alere Corporate Summary
  • Company Overview
  • Company Performance

ASTRAZENECA

  • Table 7-6: AstraZeneca Corporate Summary
  • Company Overview
  • Company Performance

BAYER

  • Table 7-7: Bayer Corporate Summary
  • Company Overview
  • Company Performance

BECTON, DICKINSON AND COMPANY

  • Table 7-8: Becton, Dickinson Corporate Summary
  • Company Overview
  • Company Performance

BELIMED

  • Table 7-9: Belimed Corporate Summary
  • Company Overview
  • Company Performance

BIOMÉRIEUX S.A.

  • Table 7-10: bioMérieux Corporate Summary
  • Company Overview
  • Company Performance

CANTEL MEDICAL CORP.

  • Table 7-11: Cantel Medical Corporate Summary
  • Company Overview
  • Company Performance

DANAHER CORPORATION

  • Table 7-12: Danaher Corporate Summary
  • Company Overview
  • Company Performance
  • Hospital Acquired Infection (HAI) Control Markets
  • February viii 2017 © Kalorama Information

ECOLAB, INC.

  • Table 7-13: Ecolab Corporate Summary
  • Company Overview
  • Company Performance

GETINGE GROUP

  • Table 7-14: Getinge AB Corporate Summary
  • Company Overview
  • Company Performance

GLAXOSMITHKLINE PLC

  • Table 7-15: GlaxoSmithKline Corporate Summary
  • Company Overview
  • Company Performance

MERCK & CO.

  • Table 7-16: Merck Corporate Summary
  • Company Overview
  • Company Performance

PFIZER, INC.

  • Table 7-17: Pfizer Corporate Summary
  • Company Overview
  • Company Performance

ROCHE

  • Table 7-18: F. Hoffman-La Roche, Ltd. Corporate Summary
  • Company Overview
  • Company Performance

SAKURA SEIKI CO., LTD.

  • Table 7-19: Sakura Seiki Corporate Summary
  • Company Overview

STERIS PLC

  • Table 7-20: Steris Corporate Summary
  • Company Overview
  • Company Performance

TSO3, INC.

  • Table 7-21: TSO3 Corporate Summary
  • Company Overview
  • Company Performance

APPENDIX: LIST OF PARTICIPANTS

  • Table A-1: List of Participants
Back to Top